[go: up one dir, main page]

EA200300248A1 - Бициклопиразолы, активные в качестве ингибиторов киназы, способ их получения и включающие их фармацевтические композиции - Google Patents

Бициклопиразолы, активные в качестве ингибиторов киназы, способ их получения и включающие их фармацевтические композиции

Info

Publication number
EA200300248A1
EA200300248A1 EA200300248A EA200300248A EA200300248A1 EA 200300248 A1 EA200300248 A1 EA 200300248A1 EA 200300248 A EA200300248 A EA 200300248A EA 200300248 A EA200300248 A EA 200300248A EA 200300248 A1 EA200300248 A1 EA 200300248A1
Authority
EA
Eurasian Patent Office
Prior art keywords
bicyclopirasoles
active
receiving
pharmaceutical compositions
kinase inhibitors
Prior art date
Application number
EA200300248A
Other languages
English (en)
Other versions
EA006381B1 (ru
Inventor
Даниеле Фанчелли
Валерия Питтала'
Марио Варази
Original Assignee
Фармация Италия С.П.А.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24549630&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA200300248(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Фармация Италия С.П.А. filed Critical Фармация Италия С.П.А.
Publication of EA200300248A1 publication Critical patent/EA200300248A1/ru
Publication of EA006381B1 publication Critical patent/EA006381B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Virology (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

Производные бициклопиразола формулы (I), как здесь указано, являются полезными для лечения заболеваний, связанных с протеинкиназами с нарушенной регуляцией.Отчет о международном поиске был опубликован 2002.06.06.
EA200300248A 2000-08-10 2001-07-25 Бициклопиразолы, активные в качестве ингибиторов киназы, способ их получения и включающие их фармацевтические композиции EA006381B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63591400A 2000-08-10 2000-08-10
PCT/EP2001/008639 WO2002012242A2 (en) 2000-08-10 2001-07-25 Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them

Publications (2)

Publication Number Publication Date
EA200300248A1 true EA200300248A1 (ru) 2003-08-28
EA006381B1 EA006381B1 (ru) 2005-12-29

Family

ID=24549630

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200300248A EA006381B1 (ru) 2000-08-10 2001-07-25 Бициклопиразолы, активные в качестве ингибиторов киназы, способ их получения и включающие их фармацевтические композиции

Country Status (29)

Country Link
US (3) US7541354B2 (ru)
EP (1) EP1320531B1 (ru)
JP (2) JP4555547B2 (ru)
KR (1) KR100904157B1 (ru)
CN (2) CN1447810A (ru)
AR (1) AR034137A1 (ru)
AT (1) ATE480539T1 (ru)
AU (2) AU8765401A (ru)
BR (1) BR0113176A (ru)
CA (1) CA2416527C (ru)
CY (1) CY1110914T1 (ru)
CZ (1) CZ2003591A3 (ru)
DE (1) DE60143041D1 (ru)
DK (1) DK1320531T3 (ru)
EA (1) EA006381B1 (ru)
EE (1) EE05405B1 (ru)
ES (1) ES2349762T3 (ru)
HU (1) HU229824B1 (ru)
IL (2) IL153997A0 (ru)
MX (1) MXPA03001169A (ru)
MY (1) MY148632A (ru)
NO (1) NO325530B1 (ru)
NZ (1) NZ524475A (ru)
PE (1) PE20020274A1 (ru)
PL (1) PL213199B1 (ru)
PT (1) PT1320531E (ru)
SK (1) SK1882003A3 (ru)
WO (1) WO2002012242A2 (ru)
ZA (1) ZA200301813B (ru)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2375360C2 (ru) * 2005-01-19 2009-12-10 Авентис Фарма С.А. Замещенные пиразолопиридины, композиции, содержащие их, способ получения и применение

Families Citing this family (115)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60143041D1 (de) * 2000-08-10 2010-10-21 Pfizer Italia Srl Bizyklische pyrazole wirksam als kinase inhibitoren, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zubereitungen
US20030195192A1 (en) * 2002-04-05 2003-10-16 Fortuna Haviv Nicotinamides having antiangiogenic activity
CA2486097A1 (en) 2002-05-15 2003-11-27 Janssen Pharmaceutica N.V. N-substituted tricyclic 3-aminopyrazoles as pdfg receptor inhibitors
WO2003097610A1 (en) * 2002-05-17 2003-11-27 Pharmacia Italia S.P.A. Aminoindazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
AU2003254337A1 (en) * 2002-07-17 2004-02-02 Pharmacia Italia S.P.A. Heterobicyclic pyrazole derivatives as kinase inhibitors
EP1527074A1 (en) * 2002-07-25 2005-05-04 Pharmacia Italia S.p.A. Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
AU2003244632A1 (en) * 2002-07-25 2004-02-25 Pharmacia Italia S.P.A. Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
US7541378B2 (en) * 2002-07-25 2009-06-02 Pfizer Italia S.R.L. Condensed heterocyclic pyrazole derivatives as kinase inhibitors
UA81790C2 (ru) * 2002-12-19 2008-02-11 Фармация Италия С.П.А. Замещенные пиролопиразольные производные как ингибиторы киназы
CA2518395A1 (en) * 2003-03-11 2004-09-23 Pharmacia Italia S.P.A. Bicyclo-pyrazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
EA010904B1 (ru) 2003-05-22 2008-12-30 НЕРВИАНО МЕДИКАЛ САЙЕНСИЗ С.р.л. Производные пиразолохиназолина: способ получения и применение в качестве ингибиторов киназ
US7141568B2 (en) 2003-07-09 2006-11-28 Pfizer Italia S.R.L. Pyrrolo[3,4-c]pyrazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
AR045037A1 (es) * 2003-07-10 2005-10-12 Aventis Pharma Sa Tetrahidro-1h-pirazolo [3,4-c] piridinas sustituidas, composiciones que las contienen y su utilizacion.
US20050043346A1 (en) * 2003-08-08 2005-02-24 Pharmacia Italia S.P.A. Pyridylpyrrole derivatives active as kinase inhibitors
ES2307040T3 (es) * 2003-08-08 2008-11-16 Pfizer Italia S.R.L. Derivados de pirimidilpirrol activos como inhibidores de cinasa.
AU2004276341B2 (en) * 2003-09-23 2011-04-14 Vertex Pharmaceuticals Incorporated Pyrazolopyrrole derivatives as protein kinase inhibitors
US7592466B2 (en) 2003-10-09 2009-09-22 Abbott Laboratories Ureas having antiangiogenic activity
EP1694686A1 (en) 2003-12-19 2006-08-30 Takeda San Diego, Inc. Kinase inhibitors
JPWO2005063241A1 (ja) * 2003-12-26 2007-07-19 小野薬品工業株式会社 ミトコンドリアベンゾジアゼピン受容体介在性疾患の予防および／または治療剤
TW200526204A (en) * 2004-02-03 2005-08-16 Pharmacia Italia Spa 1h-thieno[2,3-c]pyrazole derivatives useful as kinase inhibitors
EP1778669A2 (en) 2004-08-18 2007-05-02 Takeda San Diego, Inc. Kinase inhibitors
ATE479687T1 (de) 2004-10-15 2010-09-15 Takeda Pharmaceutical Kinaseinhibitoren
DE602005026037D1 (de) * 2004-10-27 2011-03-03 Janssen Pharmaceutica Nv Tetrahydro pyridinyl pyrazole cannabinoid modulatoren
US20060128710A1 (en) * 2004-12-09 2006-06-15 Chih-Hung Lee Antagonists to the vanilloid receptor subtype 1 (VR1) and uses thereof
AP2007004061A0 (en) 2005-01-10 2007-08-31 Galloway & Company Pyrrolopyrazoles, potent kinase inhibitors
FR2880891B1 (fr) * 2005-01-19 2007-02-23 Aventis Pharma Sa Pyrazolo pyridines substituees, compositions les contenant, procede de fabrication et utilisation
AU2006271781A1 (en) * 2005-07-15 2007-01-25 F. Hoffmann-La Roche Ag Novel heteroaryl fused cyclic amines
WO2007009898A1 (en) 2005-07-19 2007-01-25 Nerviano Medical Sciences S.R.L. 1h-thieno[2,3-c]pyrazole compounds useful as kinase inhibitors
FR2889526B1 (fr) 2005-08-04 2012-02-17 Aventis Pharma Sa 7-aza-indazoles substitues, compositions les contenant, procede de fabrication et utilisation
WO2007023382A2 (en) * 2005-08-25 2007-03-01 Pfizer Inc. Pyrimidine amino pyrazole compounds, potent kinase inhibitors
US8119655B2 (en) 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
EA014906B1 (ru) * 2005-12-01 2011-02-28 Элан Фармасьютикалз, Инк. 5-(арилсульфонил)пиразолопиперидины
JP5219150B2 (ja) * 2005-12-12 2013-06-26 ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ キナーゼ阻害薬として活性な置換ピラゾロ［４，３−ｃ］ピリジン誘導体
CA2631907A1 (en) 2005-12-12 2007-06-21 Nerviano Medical Sciences S.R.L. Substituted pyrrolo-pyrazole derivatives active as kinase inhibitors
US7618982B2 (en) 2005-12-19 2009-11-17 Nerviano Medical Sciences S.R.L. Heteroarylpyrrolopyridinones active as kinase inhibitors
JP4635089B2 (ja) * 2005-12-21 2011-02-16 ファイザー・プロダクツ・インク 有効なキナーゼ阻害剤であるカルボニルアミノピロロピラゾール
US7504513B2 (en) 2006-02-27 2009-03-17 Hoffman-La Roche Inc. Thiazolyl-benzimidazoles
WO2007099166A1 (en) * 2006-03-03 2007-09-07 Nerviano Medical Sciences S.R.L. Pyrazolo-pyridine derivatives active as kinase inhibitors
EP1999131B1 (en) 2006-03-03 2013-10-23 Nerviano Medical Sciences S.r.l. Bicyclo-pyrazoles active as kinase inhibitors
US20070213378A1 (en) * 2006-03-10 2007-09-13 Lymphosign Inc. Compounds for modulating cell proliferation, compositions and methods related thereto
AU2007258527A1 (en) * 2006-06-12 2007-12-21 Merck Sharp & Dohme Corp. Ophthalmic compositions for treating ocular hypertension
WO2008017465A1 (en) * 2006-08-10 2008-02-14 F. Hoffmann-La Roche Ag Bicyclic lactam derivatives, their manufacture and use as pharmaceutical agents
JP2010505962A (ja) 2006-10-09 2010-02-25 武田薬品工業株式会社 キナーゼ阻害剤
WO2008043745A1 (en) * 2006-10-11 2008-04-17 Nerviano Medical Sciences S.R.L. Substituted pyrrolo-pyrazole derivatives as kinase inhibitors
US8883790B2 (en) 2006-10-12 2014-11-11 Astex Therapeutics Limited Pharmaceutical combinations
EP2073803B1 (en) 2006-10-12 2018-09-19 Astex Therapeutics Limited Pharmaceutical combinations
CA2677572C (en) 2007-02-07 2012-12-18 Pfizer Inc. 3-amino-pyrrolo[3,4-c]pyrazole-5(1h,4h,6h) carbaldehyde derivatives as pkc inhibitors
EP2120933B1 (en) 2007-02-27 2015-07-08 Nerviano Medical Sciences S.r.l. Isoquinolinopyrrolopyridinones active as kinase inhibitors
CA2683695C (en) 2007-04-12 2013-06-18 Pfizer Inc. 3-amido-pyrrolo[3,4-c]pyrazole-5(1h,4h,6h) carbaldehyde derivatives
EP2003129B1 (en) 2007-06-11 2017-08-09 Nerviano Medical Sciences S.r.l. 1H-Pyrido[3,4-B]indol-1-one and 2,3,4,9-Tetrahydro-1H-Beta-Carbolin-1-one Derivatives
US20110129467A1 (en) 2008-07-24 2011-06-02 Nerviano Medical Sciences S.R.L. Therapeutic combination comprising an aurora kinase inhibitor and antiproliferative agents
WO2010057197A1 (en) 2008-11-17 2010-05-20 The Regents Of The University Of Michigan Cancer vaccine compositions and methods of using the same
CA2745596A1 (en) 2008-12-18 2010-10-28 F. Hoffmann-La Roche Ag Thiazolyl-benzimidazoles
US8440693B2 (en) 2009-12-22 2013-05-14 Novartis Ag Substituted isoquinolinones and quinazolinones
AU2010343102B2 (en) 2009-12-29 2016-03-24 Dana-Farber Cancer Institute, Inc. Type II Raf kinase inhibitors
WO2012020227A1 (en) 2010-08-11 2012-02-16 Centro Nacional De Investigaciones Oncologicas (Cnio) Tricyclic compounds for use as kinase inhibitors
RU2652638C2 (ru) 2010-12-17 2018-04-28 НЕРВИАНО МЕДИКАЛ САЙЕНСИЗ С.р.л. Замещенные пиразолхиназолиновые производные в качестве ингибиторов киназы
CN102134243A (zh) * 2011-03-04 2011-07-27 中国医学科学院医药生物技术研究所 具有抗肿瘤活性的双环氨基吡唑类衍生物
US8771682B2 (en) 2011-04-26 2014-07-08 Technische Universtität Dresden Methods and compositions for reducing interleukin-4 or interleukin-13 signaling
BR112013028281A2 (pt) 2011-05-04 2017-01-10 Forma Tm Llc compostos e composições para inibição de nampt
EP2822935B1 (en) 2011-11-17 2019-05-15 Dana-Farber Cancer Institute, Inc. Inhibitors of c-jun-n-terminal kinase (jnk)
CN104080787B (zh) 2011-11-29 2016-09-14 诺华股份有限公司 吡唑并吡咯烷化合物
JO3357B1 (ar) 2012-01-26 2019-03-13 Novartis Ag مركبات إيميدازوبيروليدينون
CN104321325B (zh) 2012-05-24 2016-11-16 诺华股份有限公司 吡咯并吡咯烷酮化合物
US10112927B2 (en) 2012-10-18 2018-10-30 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 (CDK7)
WO2014063061A1 (en) 2012-10-19 2014-04-24 Dana-Farber Cancer Institute, Inc. Hydrophobically tagged small molecules as inducers of protein degradation
CA2890359A1 (en) * 2012-11-07 2014-05-15 Zucai SUO Substituted gemcitabine aryl amide analogs and treatment methods using same
US9403827B2 (en) 2013-01-22 2016-08-02 Novartis Ag Substituted purinone compounds
US9556180B2 (en) 2013-01-22 2017-01-31 Novartis Ag Pyrazolo[3,4-d]pyrimidinone compounds as inhibitors of the P53/MDM2 interaction
US8975417B2 (en) 2013-05-27 2015-03-10 Novartis Ag Pyrazolopyrrolidine derivatives and their use in the treatment of disease
EA029312B1 (ru) 2013-05-27 2018-03-30 Новартис Аг Производные имидазопирролидинона и их применение при лечении заболеваний
KR20160012197A (ko) 2013-05-28 2016-02-02 노파르티스 아게 피라졸로-피롤리딘-4-온 유도체 및 질환의 치료에서의 그의 용도
MX2015016421A (es) 2013-05-28 2016-03-03 Novartis Ag Derivados de pirazolo-pirrolidin-4-ona como inhibidores de bet y su uso en el tratamiento de enfermedades.
EP3057956B1 (en) 2013-10-18 2021-05-05 Dana-Farber Cancer Institute, Inc. Polycyclic inhibitors of cyclin-dependent kinase 7 (cdk7)
ES2676734T3 (es) 2013-10-18 2018-07-24 Syros Pharmaceuticals, Inc. Compuestos heteroatómicos útiles para el tratamiento de enfermedades proliferativas
AU2014351413B2 (en) 2013-11-21 2017-06-01 Novartis Ag Pyrrolopyrrolone derivatives and their use as BET inhibitors
JP2017516853A (ja) * 2014-05-23 2017-06-22 ミングサイト ファーマシューティカルズ，インク． 自己免疫性疾患の処置
AU2015337607B2 (en) 2014-10-31 2020-04-09 Ube Corporation Substituted dihydropyrrolopyrazole compound
US10870651B2 (en) 2014-12-23 2020-12-22 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 (CDK7)
WO2016109684A2 (en) 2014-12-30 2016-07-07 Novira Therapeutics, Inc. Derivatives and methods of treating hepatitis b infections
CN104530045A (zh) * 2015-01-14 2015-04-22 中国药科大学 吡唑并[4,3-c]四氢吡啶类c-Met激酶抑制剂及其制备方法和用途
AU2016243529B2 (en) 2015-03-27 2021-03-25 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinases
MY198769A (en) 2015-06-04 2023-09-25 Aurigene Oncology Ltd Substituted heterocyclic derivatives as cdk inhibitors
US10702527B2 (en) 2015-06-12 2020-07-07 Dana-Farber Cancer Institute, Inc. Combination therapy of transcription inhibitors and kinase inhibitors
JP6787314B2 (ja) 2015-06-15 2020-11-18 宇部興産株式会社 置換ジヒドロピロロピラゾール誘導体
JP7028766B2 (ja) 2015-09-09 2022-03-02 ダナ－ファーバー キャンサー インスティテュート， インコーポレイテッド サイクリン依存性キナーゼの阻害剤
CA3029688A1 (en) 2016-06-29 2018-01-04 Novira Therapeutics, Inc. Oxadiazepinone derivatives and their use in the treatment of hepatitis b infections
WO2018005883A1 (en) 2016-06-29 2018-01-04 Novira Therapeutics, Inc. Diazepinone derivatives and their use in the treatment of hepatitis b infections
NZ750781A (en) 2016-09-09 2025-06-27 Novartis Ag Compounds and compositions as inhibitors of endosomal toll-like receptors
DK3433256T3 (da) 2016-10-24 2019-10-28 Astrazeneca 6,7,8,9-tetrahydro-3h-pyrazolo[4,3-f]isoquinolinderivat, der er anvendeligt til behandling af cancer
ES2766249T3 (es) 2017-01-30 2020-06-12 Astrazeneca Ab Moduladores del receptor de estrógeno
WO2018222601A1 (en) 2017-05-31 2018-12-06 Chemocentryx, Inc. 5-5 FUSED RINGS AS C5a INHIBITORS
EP3630775B1 (en) 2017-05-31 2022-12-14 ChemoCentryx, Inc. 6-5 FUSED RINGS AS C5a INHIBITORS
US10435429B2 (en) 2017-10-03 2019-10-08 Nucorion Pharmaceuticals, Inc. 5-fluorouridine monophosphate cyclic triester compounds
WO2019072942A1 (en) 2017-10-11 2019-04-18 F. Hoffmann-La Roche Ag BICYCLIC COMPOUNDS FOR USE AS INHIBITORS OF KINASE RIP1
KR20200083552A (ko) * 2017-11-02 2020-07-08 아이쿠리스 게엠베하 운트 코. 카게 B형 간염 바이러스 (hbv)에 활성인 신규 고활성 피라졸로-피페리딘 치환된 인돌-2-카르복스아미드
EP3728203B1 (en) * 2017-12-22 2024-03-13 ChemoCentryx, Inc. DIARYL SUBSTITUTED 6,5-FUSED RING COMPOUNDS AS C5aR INHIBITORS
US10759807B2 (en) * 2017-12-22 2020-09-01 Chemocentryx, Inc. Diaryl substituted 5,5-fused ring compounds as C5aR inhibitors
WO2019139920A1 (en) 2018-01-10 2019-07-18 Nucorion Pharmaceuticals, Inc. Phosphor(n)amidatacetal and phosph(on)atalcetal compounds
US11427550B2 (en) 2018-01-19 2022-08-30 Nucorion Pharmaceuticals, Inc. 5-fluorouracil compounds
ES2993034T3 (en) 2018-04-02 2024-12-20 Chemocentryx Inc Prodrugs of fused-bicyclic c5ar antagonists
AU2019295632B2 (en) 2018-06-25 2025-03-06 Dana-Farber Cancer Institute, Inc. Taire family kinase inhibitors and uses thereof
CN110878042B (zh) * 2018-09-05 2021-06-01 新发药业有限公司 一种n-取代基哌啶-3-酮的制备方法
WO2020100944A1 (ja) 2018-11-14 2020-05-22 宇部興産株式会社 ジヒドロピロロピラゾール誘導体
JP7660063B2 (ja) * 2018-12-28 2025-04-10 ダナ－ファーバー キャンサー インスティテュート， インコーポレイテッド サイクリン依存性キナーゼ７のインヒビターおよびそれらの使用
US20220213088A1 (en) * 2019-04-30 2022-07-07 Valo Health, Inc. Inhibiting usp36
AU2020315394A1 (en) 2019-07-17 2022-02-17 Nucorion Pharmaceuticals, Inc. Cyclic deoxyribonucleotide compounds
US12491251B2 (en) 2019-08-05 2025-12-09 Dana-Farber Cancer Institute, Inc. Degraders of cyclin-dependent kinase 7 (CDK7) and uses thereof
US20230114207A1 (en) * 2019-12-24 2023-04-13 Dana-Farber Cancer Institute, Inc. The combination of cyclin dependent kinase 7 inhibitor and immunotherapy for treatment of cancer
CN115605492B (zh) 2020-04-21 2025-09-16 配体制药股份有限公司 核苷酸前药化合物
KR20230005270A (ko) 2020-04-24 2023-01-09 아스트라제네카 아베 약학적 제형
IL297216A (en) 2020-04-24 2022-12-01 Astrazeneca Ab Dosage regimen for the treatment of cancer
CN115073471B (zh) * 2021-03-11 2023-03-21 沈阳药科大学 吡唑并四氢吡咯类衍生物、其制备方法和在医药上的应用
CN113563346A (zh) * 2021-08-19 2021-10-29 守恒(厦门)医疗科技有限公司 吡咯[3,4-c]并吡唑二酰胺类衍生物及其在抗肿瘤药物中的应用
CN115057860B (zh) * 2022-05-20 2024-02-09 四川大学华西医院 一种erk抑制剂及其制药用途

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3423414A (en) * 1966-01-13 1969-01-21 Ciba Geigy Corp Pyrazolopyridines
US3526633A (en) * 1968-03-06 1970-09-01 American Cyanamid Co Substituted 2,4,5,6-tetrahydropyrrolo(3,4-c)pyrazoles
US3947467A (en) * 1973-08-02 1976-03-30 Eli Lilly And Company 3-(5-Nitro-2-imidazolyl) pyrazoles
JPS5163193A (ja) * 1974-11-26 1976-06-01 Yoshitomi Pharmaceutical Tetorahidoropirazoropirijinkagobutsuno seizoho
EP0707585A1 (en) * 1993-07-06 1996-04-24 Pfizer Inc. Bicyclic tetrahydro pyrazolopyridines
US5508300A (en) * 1994-01-14 1996-04-16 Pfizer Inc. Dihydro pyrazolopyrroles, compositions and use
WO1996012720A1 (en) * 1994-10-20 1996-05-02 Pfizer Inc. Bicyclic tetrahydro pyrazolopyridines and their use as medicaments
US5593997A (en) * 1995-05-23 1997-01-14 Pfizer Inc. 4-aminopyrazolo(3-,4-D)pyrimidine and 4-aminopyrazolo-(3,4-D)pyridine tyrosine kinase inhibitors
US6008230A (en) * 1995-10-16 1999-12-28 Fujisawa Pharmaceutical Co., Ltd. Quinoline compounds as H+ -ATPases
GB9608435D0 (en) * 1996-04-24 1996-06-26 Celltech Therapeutics Ltd Chemical compounds
TR200002617T2 (tr) * 1997-12-22 2000-11-21 Bayer Corporation Aril ve heteroaril sübstitüentli heterosiklik üreler kullanılarak RAF kinazın inhibe edilmesi
DE60143041D1 (de) * 2000-08-10 2010-10-21 Pfizer Italia Srl Bizyklische pyrazole wirksam als kinase inhibitoren, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zubereitungen
UA81790C2 (ru) * 2002-12-19 2008-02-11 Фармация Италия С.П.А. Замещенные пиролопиразольные производные как ингибиторы киназы
US7141568B2 (en) * 2003-07-09 2006-11-28 Pfizer Italia S.R.L. Pyrrolo[3,4-c]pyrazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
JP5219150B2 (ja) * 2005-12-12 2013-06-26 ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ キナーゼ阻害薬として活性な置換ピラゾロ［４，３−ｃ］ピリジン誘導体

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2375360C2 (ru) * 2005-01-19 2009-12-10 Авентис Фарма С.А. Замещенные пиразолопиридины, композиции, содержащие их, способ получения и применение

Also Published As

Publication number Publication date
PL213199B1 (pl) 2013-01-31
CA2416527C (en) 2009-12-22
EA006381B1 (ru) 2005-12-29
KR100904157B1 (ko) 2009-06-23
AU8765401A (en) 2002-02-18
PE20020274A1 (es) 2002-03-31
US20070191386A1 (en) 2007-08-16
DE60143041D1 (de) 2010-10-21
US8273765B2 (en) 2012-09-25
PL360663A1 (en) 2004-09-20
MXPA03001169A (es) 2003-06-30
NO325530B1 (no) 2008-06-09
JP2010111677A (ja) 2010-05-20
MY148632A (en) 2013-05-15
CZ2003591A3 (cs) 2003-06-18
AR034137A1 (es) 2004-02-04
DK1320531T3 (da) 2011-01-03
ATE480539T1 (de) 2010-09-15
JP2004505977A (ja) 2004-02-26
HUP0300741A2 (hu) 2003-11-28
KR20030027008A (ko) 2003-04-03
ES2349762T3 (es) 2011-01-11
US20030171357A1 (en) 2003-09-11
AU2001287654B2 (en) 2006-12-14
CA2416527A1 (en) 2002-02-14
SK1882003A3 (en) 2003-06-03
JP5185243B2 (ja) 2013-04-17
EP1320531B1 (en) 2010-09-08
NO20030381D0 (no) 2003-01-24
US7531531B2 (en) 2009-05-12
IL153997A0 (en) 2003-07-31
EE05405B1 (et) 2011-04-15
US7541354B2 (en) 2009-06-02
HUP0300741A3 (en) 2005-12-28
IL153997A (en) 2014-01-30
US20090221632A1 (en) 2009-09-03
WO2002012242A2 (en) 2002-02-14
CY1110914T1 (el) 2014-02-12
CN1447810A (zh) 2003-10-08
ZA200301813B (en) 2004-06-22
NZ524475A (en) 2004-11-26
JP4555547B2 (ja) 2010-10-06
NO20030381L (no) 2003-02-24
EP1320531A2 (en) 2003-06-25
HU229824B1 (en) 2014-08-28
BR0113176A (pt) 2003-06-17
WO2002012242A3 (en) 2002-06-06
PT1320531E (pt) 2010-10-27
EE200300054A (et) 2004-12-15
CN102060857A (zh) 2011-05-18

Similar Documents

Publication Publication Date Title
EA200300248A1 (ru) Бициклопиразолы, активные в качестве ингибиторов киназы, способ их получения и включающие их фармацевтические композиции
EA200400073A1 (ru) Пирролопиримидины как ингибиторы протеинкиназы
EA200200862A1 (ru) Пирролзамещенный 2-индолинон и промежуточный пиррол, фармацевтическая композиция (варианты), способ модулирования каталитической активности протеинкиназы, способ лечения или профилактики нарушения в организме, связанного с протеинкиназой
TR200201505T2 (tr) Terapötik maddeler olarak pirazolopirimidinler
EA200100971A1 (ru) Новые соединения и композиции в качестве ингибиторов протеазы
EA200400289A1 (ru) Производные аминоизоксазола, активные в качестве ингибиторов киназы
DE60214703D1 (de) Thiazolverbindungen, die sich als inhibitoren von proteinkinasen eignen
EA200500299A1 (ru) Пиразольные композиции, используемые в качестве ингибиторов gsk-3
ATE466580T1 (de) Azolylaminoazine als proteinkinasehemmer
ATE468336T1 (de) Azolylaminoazine als proteinkinasehemmer
ATE365733T1 (de) Zusammensetzungen brauchbar als protein-kinase- inhibitoren
MXPA02005844A (es) Inhibidores de cinasas de proteina.
NO944643L (no) Protein-kinase-C-hemmere
NO20053470L (no) Triazolopyridaziner som proteinkinase-inhibitorer
YU84603A (sh) Novi inhibitori tirozin kinaze
EA200400953A1 (ru) Замещённые пиридиноны в качестве модуляторов map-киназы p38
ATE371656T1 (de) Heteroaryl-pyrimidinderivate als jak-inhibitoren
EA200501009A1 (ru) Замещённые пирролопиразольные производные в качестве ингибиторов киназы
NO20025450D0 (no) Ny farmasöytisk sammensetning
EA200300171A1 (ru) Циклопентаноиндолы, композиции, содержащие данные соединения, и способы лечения
EA200400283A1 (ru) Производные аминофталазинона, активные как ингибиторы киназ, способ их получения и содержащие их фармацевтические композиции
BR0008056A (pt) Pirrolocarbazóis e isoindolonas cìclicas fundidas substituìdas
BRPI0407841A (pt) inibidores heterocìclicos de quinase
EA200400475A1 (ru) Замещенные производные бензимидазола и их применение для лечения злокачественной опухоли
DE60115466D1 (de) Wirkstoffvorläufer von imidazopyridin-derivaten

Legal Events

Date Code Title Description
PD4A Registration of transfer of a eurasian patent in accordance with the succession in title
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU